HK1039272A1 - Prodrug compounds and process for preparation thereof - Google Patents
Prodrug compounds and process for preparation thereofInfo
- Publication number
- HK1039272A1 HK1039272A1 HK01108566.6A HK01108566A HK1039272A1 HK 1039272 A1 HK1039272 A1 HK 1039272A1 HK 01108566 A HK01108566 A HK 01108566A HK 1039272 A1 HK1039272 A1 HK 1039272A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- leu
- prodrug
- prodrugs
- therapeutic agent
- ssala
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Cephalosporin Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11179398P | 1998-12-11 | 1998-12-11 | |
| US11931299P | 1999-02-08 | 1999-02-08 | |
| PCT/US1999/030393 WO2000033888A2 (en) | 1998-12-11 | 1999-12-10 | Prodrug compounds and process for preparation thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1039272A1 true HK1039272A1 (en) | 2002-04-19 |
Family
ID=26809248
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK01108566.6A HK1039272A1 (en) | 1998-12-11 | 2001-12-06 | Prodrug compounds and process for preparation thereof |
Country Status (14)
| Country | Link |
|---|---|
| EP (1) | EP1144011B1 (pt) |
| JP (1) | JP2003518000A (pt) |
| AT (1) | ATE460180T1 (pt) |
| AU (1) | AU773420B2 (pt) |
| CA (1) | CA2354766A1 (pt) |
| CY (1) | CY1111094T1 (pt) |
| DE (1) | DE69942128D1 (pt) |
| DK (1) | DK1144011T3 (pt) |
| ES (1) | ES2342637T3 (pt) |
| HK (1) | HK1039272A1 (pt) |
| IL (2) | IL143666A0 (pt) |
| NZ (1) | NZ512171A (pt) |
| PT (1) | PT1144011E (pt) |
| WO (1) | WO2000033888A2 (pt) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7462605B2 (en) | 1998-01-23 | 2008-12-09 | Celmed Oncology (Usa), Inc. | Phosphoramidate compounds and methods of use |
| PT1045897E (pt) | 1998-01-23 | 2002-07-31 | Newbiotics Inc | Agentes terapeuticos por catalise enzimatica |
| IL140700A0 (en) | 1998-07-13 | 2002-02-10 | Univ Texas | Cancer treatment methods using therapeutic conjugates that bind to aminophospholipids |
| US6818213B1 (en) | 1998-07-13 | 2004-11-16 | Board Of Regents, The University Of Texas System | Cancer treatment compositions comprising therapeutic conjugates that bind to aminophospholipids |
| US7425541B2 (en) | 1998-12-11 | 2008-09-16 | Medarex, Inc. | Enzyme-cleavable prodrug compounds |
| JP2002544242A (ja) | 1999-05-14 | 2002-12-24 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | 酵素活性化抗腫瘍プロドラッグ化合物 |
| US6613879B1 (en) | 1999-05-14 | 2003-09-02 | Boehringer Ingelheim Pharma Kg | FAP-activated anti-tumour compounds |
| WO2001007088A2 (en) * | 1999-07-22 | 2001-02-01 | Newbiotics, Inc. | Methods for treating therapy-resistant tumors |
| US6683061B1 (en) | 1999-07-22 | 2004-01-27 | Newbiotics, Inc. | Enzyme catalyzed therapeutic activation |
| WO2001007087A2 (en) * | 1999-07-22 | 2001-02-01 | Newbiotics, Inc. | Enzyme catalyzed anti-infective therapeutic agents |
| DE10018617A1 (de) * | 2000-01-13 | 2001-10-31 | Joerg G Moser | Cyclodextrin-Dimere mit Peptid-Spacerstrukturen zur Entgiftung von pharmazeutischen Wirkstoffen hohen Nebenwirkungspotentials |
| HUP0300590A2 (hu) | 2000-03-15 | 2003-07-28 | Bristol-Myers Squibb Pharma Company | Peptidázzal hasítható, célzott antineoplasztikus szerek és terápiás alkalmazásuk |
| AU7130101A (en) * | 2000-06-14 | 2001-12-24 | Corixa Corp | Enzyme-cleavable prodrug compounds |
| EP1294403A2 (en) * | 2000-06-14 | 2003-03-26 | Corixa Corporation | Tripeptide prodrug compounds |
| AU2001266853B2 (en) | 2000-06-14 | 2005-02-17 | Medarex, Inc. | Prodrug compounds with an oligopeptide having an isoleucine residue |
| WO2002015700A1 (en) * | 2000-08-24 | 2002-02-28 | Coulter Pharmaceutical, Inc. | Prodrugs activated by plasmin and their use in cancer chemotherapy |
| AU1602902A (en) * | 2000-10-27 | 2002-05-06 | Aventis Pharma Sa | A combination comprising camptothecin and a stilbene derivative for the treatment of cancer |
| JP2006516948A (ja) * | 2000-11-14 | 2006-07-13 | ニュー リバー ファーマシューティカルズ インコーポレイテッド | 硫酸アバカビルを含有する新規な薬剤化合物および同化合物の製造ならびに使用方法 |
| WO2002060488A1 (en) * | 2001-01-30 | 2002-08-08 | Universite Catholique De Louvain | Anti-tumor compounds |
| KR20030033007A (ko) * | 2001-05-31 | 2003-04-26 | 코울터 파머수티컬, 인코포레이티드 | 세포독소, 약물전구체, 링커 및 이에 유용한 안정화제 |
| DE60239679D1 (de) * | 2001-06-11 | 2011-05-19 | Medarex Inc | Methode für die ausarbeitung von cd10-aktivierten prodrug-verbindungen |
| FR2825928B1 (fr) * | 2001-06-18 | 2004-04-02 | Ecole Norm Superieure Cachan | Composition pharmaceutique pour le diagnostic, la prevention ou le traitement d'une pathologie tumorale, comprenant un agent modulateur de l'etat polymerisation de l'actine |
| WO2003094972A2 (en) * | 2002-05-10 | 2003-11-20 | Boehringer Ingelheim Pharma Gmbh & Co Kg | Fap-activated anti-tumor prodrugs |
| US7879801B2 (en) * | 2002-07-15 | 2011-02-01 | Board Of Regents, The University Of Texas System | Compositions comprising cell-impermeant duramycin derivatives |
| US7511124B2 (en) | 2002-07-15 | 2009-03-31 | Board Of Regents, The University Of Texas System | Compositions comprising phosphatidylethanolamine-binding peptides linked to anti-viral agents |
| US7378386B2 (en) | 2002-07-15 | 2008-05-27 | Board Of Regents, The University Of Texas System | Anti-viral treatment methods using phosphatidylethanolamine-binding peptide derivatives |
| US7678386B2 (en) | 2002-07-15 | 2010-03-16 | Board Of Regents The University Of Texas | Liposomes coated with selected antibodies that bind to aminophospholipids |
| US7384909B2 (en) | 2002-07-15 | 2008-06-10 | Board Of Regents, The University Of Texas System | Anti-viral treatment methods using phosphatidylethanolamine-binding peptides linked to anti-viral agents |
| ATE430593T1 (de) | 2003-10-28 | 2009-05-15 | Medtronic Inc | Verfahren zur herstellung von vernetzten materialien und bioprothetischen vorrichtungen |
| EP1718145A4 (en) | 2004-02-02 | 2012-03-07 | Biosight Ltd | CONJUGATES FOR CANCER THERAPY AND DIAGNOSIS |
| WO2006095345A2 (en) | 2005-03-08 | 2006-09-14 | Ramot At Tel-Aviv University Ltd. | Targeted drug-carrying bacteriophages |
| EP1993608A1 (en) * | 2006-03-10 | 2008-11-26 | Diatos | Anticancer drugs conjugated to antibody via an enzyme cleavable linker |
| TWI447124B (zh) | 2006-12-01 | 2014-08-01 | Medarex Llc | 結合ｃｄ２２的人類抗體與其應用 |
| CL2007003622A1 (es) | 2006-12-13 | 2009-08-07 | Medarex Inc | Anticuerpo monoclonal humano anti-cd19; composicion que lo comprende; y metodo de inhibicion del crecimiento de celulas tumorales. |
| IN2009KN02404A (pt) | 2006-12-14 | 2015-08-07 | Medarex Inc | |
| TWI412367B (zh) | 2006-12-28 | 2013-10-21 | Medarex Llc | 化學鏈接劑與可裂解基質以及其之綴合物 |
| KR20090122439A (ko) | 2007-02-21 | 2009-11-30 | 메다렉스, 인코포레이티드 | 단일 아미노산을 갖는 화학적 링커 및 이의 접합체 |
| EP1977765A1 (en) * | 2007-04-03 | 2008-10-08 | Diatos | Peptide prodrugs |
| WO2013151774A1 (en) | 2012-04-04 | 2013-10-10 | Halozyme, Inc. | Combination therapy with an anti - hyaluronan agent and a tumor - targeted taxane |
| AU2013369261B2 (en) * | 2012-12-28 | 2018-08-09 | Cobiores Nv | Minimally toxic prodrugs |
| WO2014147124A1 (en) | 2013-03-21 | 2014-09-25 | Sanofi-Aventis Deutschland Gmbh | Synthesis of hydantoin containing peptide products |
| US10450343B2 (en) | 2013-03-21 | 2019-10-22 | Sanofi-Aventis Deutschland Gmbh | Synthesis of cyclic imide containing peptide products |
| WO2014197816A1 (en) * | 2013-06-06 | 2014-12-11 | Massachusetts Institute Of Technology | Stimulus responsive nanocomplexes and methods of use thereof |
| JP2018535987A (ja) | 2015-12-03 | 2018-12-06 | バイオサイト リミテッド | 癌療法のためのコンジュゲートの塩 |
| BR112018011177A2 (pt) | 2015-12-03 | 2018-11-21 | Biosight Ltd | conjugados de citarabina para terapia de câncer |
| CN109021065B (zh) * | 2017-06-08 | 2021-10-01 | 复旦大学 | 一种制备海兔毒素Dolastatin10的方法 |
| EP4267188A1 (en) | 2020-12-22 | 2023-11-01 | Cobiores NV | Compounds comprising a tetrapeptidic moiety |
| WO2022167664A1 (en) | 2021-02-07 | 2022-08-11 | Cobiores Nv | Compounds comprising a tetrapeptidic moiety |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0037388B1 (fr) * | 1980-03-31 | 1984-12-12 | Institut International De Pathologie Cellulaire Et Moleculaire | Formes pharmaceutiques, leur préparation et les compositions qui les contiennent |
| US5155210A (en) * | 1990-09-11 | 1992-10-13 | Brunswick Corporation | Methods of conjugating actinomycin d |
| JP2610792B2 (ja) * | 1993-02-26 | 1997-05-14 | 株式会社ディ・ディ・エス研究所 | 多糖誘導体および薬物担体 |
| DE69535665T2 (de) | 1994-08-19 | 2009-04-02 | La Region Wallonne | Konjugate enthaltend ein antitumorales mittel und deren verwendung |
| JP2001501601A (ja) * | 1996-09-12 | 2001-02-06 | メルク エンド カンパニー インコーポレーテッド | 前立腺ガンの治療において有用な共役体 |
| HRP970566A2 (en) * | 1996-10-30 | 1998-08-31 | Jones Deborah Defeo | Conjugates useful in the treatment of prostate canser |
| AU7582298A (en) * | 1997-05-19 | 1998-12-11 | Johns Hopkins University School Of Medicine, The | Tissue specific prodrug |
| AU740597B2 (en) * | 1997-07-10 | 2001-11-08 | Merck & Co., Inc. | Conjugates useful in the treatment of prostate cancer |
| SK8282000A3 (en) * | 1997-12-02 | 2000-11-07 | Merck & Co Inc | Conjugates useful in the treatment of prostate cancer, pharmaceutical composition containing the same and use thereof |
-
1999
- 1999-12-10 IL IL14366699A patent/IL143666A0/xx active IP Right Grant
- 1999-12-10 NZ NZ512171A patent/NZ512171A/en not_active IP Right Cessation
- 1999-12-10 AU AU23733/00A patent/AU773420B2/en not_active Ceased
- 1999-12-10 CA CA002354766A patent/CA2354766A1/en not_active Abandoned
- 1999-12-10 JP JP2000586378A patent/JP2003518000A/ja active Pending
- 1999-12-10 EP EP99967462A patent/EP1144011B1/en not_active Expired - Lifetime
- 1999-12-10 DE DE69942128T patent/DE69942128D1/de not_active Expired - Lifetime
- 1999-12-10 WO PCT/US1999/030393 patent/WO2000033888A2/en active IP Right Grant
- 1999-12-10 PT PT99967462T patent/PT1144011E/pt unknown
- 1999-12-10 DK DK99967462.5T patent/DK1144011T3/da active
- 1999-12-10 AT AT99967462T patent/ATE460180T1/de active
- 1999-12-10 ES ES99967462T patent/ES2342637T3/es not_active Expired - Lifetime
-
2001
- 2001-06-10 IL IL143666A patent/IL143666A/en not_active IP Right Cessation
- 2001-12-06 HK HK01108566.6A patent/HK1039272A1/xx not_active IP Right Cessation
-
2010
- 2010-06-10 CY CY20101100510T patent/CY1111094T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CY1111094T1 (el) | 2015-10-07 |
| WO2000033888A2 (en) | 2000-06-15 |
| ES2342637T3 (es) | 2010-07-09 |
| CA2354766A1 (en) | 2000-06-15 |
| JP2003518000A (ja) | 2003-06-03 |
| NZ512171A (en) | 2004-07-30 |
| WO2000033888A9 (en) | 2001-05-10 |
| DE69942128D1 (de) | 2010-04-22 |
| ATE460180T1 (de) | 2010-03-15 |
| AU773420B2 (en) | 2004-05-27 |
| PT1144011E (pt) | 2010-06-16 |
| IL143666A (en) | 2009-02-11 |
| DK1144011T3 (da) | 2010-07-05 |
| EP1144011A2 (en) | 2001-10-17 |
| IL143666A0 (en) | 2002-04-21 |
| AU2373300A (en) | 2000-06-26 |
| WO2000033888A3 (en) | 2001-11-08 |
| EP1144011B1 (en) | 2010-03-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL143666A0 (en) | Prodrug compounds and process for preparation thereof | |
| US7442386B2 (en) | Synthesis and use of reagents for improved DNA lipofection and/or slow release prodrug and drug therapies | |
| EP0781778B1 (en) | Paclitaxel prodrugs, method for preparation as well as their use in selective chemotherapy | |
| Kumar et al. | Targeted inhibition of hedgehog signaling by cyclopamine prodrugs for advanced prostate cancer | |
| CA2478066A1 (en) | Amphiphilic compounds and vesicles/liposomes for organ-specific drug targeting | |
| WO1997018207A3 (en) | Novel macrocyclic compounds as metalloprotease inhibitors | |
| IL133585A0 (en) | Soluble prodrugs of paclitaxel | |
| AU2002324723A1 (en) | Synthesis and use of reagents for improved DNA lipofection and/or slow release pro-drug and drug therapies | |
| AU2002359164A1 (en) | Use of oxindole derivatives in the treatment of dementia related diseases, alzheimer's disease and conditions associated with glycogen synthase kinase-3 | |
| IL159843A0 (en) | Amino-phthalazinone derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them | |
| GB0330042D0 (en) | Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions them | |
| WO2001085142A8 (en) | Compositions and methods for protecting cells during cancer chemotherapy and radiotherapy | |
| JP2003528851A (ja) | セラミド誘導体と使用方法 | |
| WO2014013995A1 (ja) | KRAS遺伝子発現抑制RNAi医薬組成物 | |
| CN113150030A (zh) | 氧杂二环庚烷前药 | |
| DE69917281T2 (de) | Coumarin und damit verwandte aromatische polymere prodrugs | |
| EP1545479A4 (en) | EZETIMIB COMPOSITIONS AND METHOD FOR THE TREATMENT OF CHOLESTERIN-ASSOCIATED GOOD AND EVIL TUMORS | |
| AU7385398A (en) | Novel macrocyclic compounds as metalloprotease inhibitors | |
| WO2015186770A1 (ja) | ＣＫＡＰ５遺伝子発現抑制ＲＮＡｉ医薬組成物 | |
| US20200277251A1 (en) | Novel antibacterial compounds and methods of making and using same | |
| Sflakidou et al. | Synthesis and antiproliferative activities of steroidal lactam conjugates bearing a new nitrogen mustard | |
| JPH09235293A (ja) | 新規トリテルペン | |
| CN103183722A (zh) | 一种乙二醛酶ⅰ抑制剂及其制备方法和医药用途 | |
| JPS6317840B2 (pt) | ||
| HUP0103557A2 (hu) | Antraciklinszármazék alkalmazása májtumor kezelésére |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20131210 |